| Date | Title | Description |
| 10.09.2026 | Claret Capital Secures €575M for European Tech, Life Sciences Growth | Claret Capital Partners has finalized its €575 million Fund IV. This significant growth debt fund targets Europe's burgeoning technology and life sciences sectors. It provides flexible, non-dilutive capital. The firm exceeded its €500 milli... |
| 07.09.2026 | Claret Capital Partners exceeds target with €575M growth debt fund for European innovators | Claret Capital Partners has closed its fourth European Growth Capital Fund at €575 million, exceeding its €500 million target. Including affiliated discretionary mandates, the fund will make growth debt investments in technology, life scien... |
| 07.09.2026 | Claret Capital Partners Raises €575M for European Growth | Claret Capital Partners Closes €575M Fund IV
London-based Claret Capital Partners has raised €575 million through Fund IV and an affiliated discretionary mandate. This surpassed its original €500 million fundraising target. The firm complet... |
| 29.06.2026 | Andera Partners joins the European Life Sciences Coalition (ELSC) with the aim to support the mobilization of capital for life sciences innovation in Europe. | Andera Partners joins the European Life Sciences Coalition (ELSC), alongside Forbion, HealthCap, Novo Holdings, Omega Funds, Sofinnova Partners, Van Lanschot Kempen, VIB, BioInnovation Institute, 4BIO Capital, Cooley and Covington.
Launched... |
| 24.04.2025 | Inventiva annonce la publication dans Clinical Gastroenterology and Hepatology de l’analyse de nouvelles signatures de biomarqueurs prédictives de la réponse histologique chez les patients atteints de... | ► Des signatures de biomarqueurs ont été développées pour prédire la réponse histologique au traitement par lanifibranor chez les patients atteints de MASH avec fibrose
► Les signatures de biomarqueurs développées pour l’amélioration de la ... |
| 24.04.2025 | Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanif... | ► Biomarker signatures were developed to predict histological treatment response to lanifibranor treatment in patients with MASH and fibrosis
► The biomarker signatures developed for fibrosis improvement, MASH resolution and composite histo... |
| 26.03.2025 | Inventiva reports its 2024 full year results and provides a business update | Revenues of €9.2 million for the full year of 2024 Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million Structured Financing closed with aggregate gross proceeds of €116 million Last patient... |
| 26.03.2025 | Inventiva publie ses résultats financiers annuels 2024 et fait le point sur son activité | Chiffre d'affaires de 9,2 millions d'euros pour l’année 2024 Trésorerie et équivalents de trésorerie à 96,6 millions d’euros au 31 décembre 2024 Levée d’un produit brut de 116 millions d’euros dans le cadre de la première tranche du Finance... |
| 26.03.2025 | Inventiva reports its 2024 full year results and provides a business update | Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million Structured Financing closed with aggregate gross proceeds of €116 millionLast patient s... |
| 24.01.2025 | Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux | Daix (France), New York City (New York, United States), January 24, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecu... |
| 16.12.2024 | Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million | Inventiva secures €21.4 million leading to completion of the first tranche of the financing for c. €116 million, part of the multi-tranche equity financing of up to €348 million announced on October 14, 2024.
Proceeds from the completed fir... |
| 12.12.2024 | Results of the votes of the Combined Shareholders’ General Meeting of December 11, 2024 | Daix (France), New York City (New York, United States), December 11, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies f... |
| 20.11.2024 | Combined General Meeting of December 11, 2024 - Availability of the preparatory documents | Daix (France), Long Island City (New York, United States), November 20, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatm... |
| 20.11.2024 | Combined General Meeting of December 11, 2024 - Availability of the preparatory documents | Daix (France), Long Island City (New York, United States), November 20, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatm... |
| 20.11.2024 | Statement of total voting rights and shares forming the company’s share capital as of November 4, 2024 | Article R. 22-10-23 of the French Commercial Code
Market : Euronext Paris
ISIN code / Mnemo : FR0013233012 / IVA
Web site : www.inventivapharma.com
Date Number of Shares Outstanding Total voting rights,
gross (1) Total voting rights,
net (2... |
| 20.11.2024 | Information relative au nombre total de droits de vote et d’actions composant le capital social au 4 novembre 2024 | Article R. 22-10-23 du Code de commerce
Place de cotation : Euronext Paris
Code ISIN / Mnémo : FR0013233012 / IVA
Site web : www.inventivapharma.com
Date Nombre de titres composant le capital en circulation Nombre total de droits
de vote br... |
| 20.11.2024 | Statement of total voting rights and shares forming the company’s share capital as of November 4, 2024 | Article R. 22-10-23 of the French Commercial Code
Market : Euronext Paris
ISIN code / Mnemo : FR0013233012 / IVA
Web site : www.inventivapharma.com
Date Number of Shares Outstanding Total voting rights,
gross (1) Total voting rights,
net (2... |
| 15.11.2024 | Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® lat... | Data will be presented on Monday, November 18th as a late breaker poster at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 in San Diego.LEGEND achieved its primary efficacy endpoint by significantly... |
| 30.10.2024 | Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH | The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.
The recommendation was based on the unblinded review by the DMC of safety... |
| 21.10.2024 | Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024 | Daix (France), Long Island City (New York, United States), October 21, 2024 - Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small mol... |
| 14.10.2024 | Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants | Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small mol... |
| 14.10.2024 | Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study | Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohe... |
| 14.10.2024 | Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants | Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small mol... |
| 14.10.2024 | Inventiva annonce la mise à disposition d'un prospectus dans le cadre de son financement par l’émission d’actions ordinaires et de bons de souscription d’action préfinancés | Daix (France), Long Island City (New York, États-Unis), le 14 octobre 2024 – Inventiva (Euronext Paris et Nasdaq: IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement clinique de petites molécu... |
| 25.09.2024 | Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results | Recruitment in NATiV3 clinical trial progresses with over 85% of the targeted number of patients enrolled in the main cohort and a statistical powering of the study expected to be superior to 95% for both doses evaluated in the trial.
Basel... |
| 31.07.2024 | Inventiva Reports Preliminary 2024 First-Half Financial Information¹ | Cash and cash equivalents at €10.1 million as of June 30, 2024, compared to cash and cash equivalents at €26.9 million, €0.012 million of short-term deposits and €9.03 million of long-term deposits as of December 31, 2023.
On July 18, 2024,... |
| 25.07.2024 | Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor | Japanese Patent Office approved Inventiva’s patent application relating to the use of lanifibranor for the treatment of cirrhosis.1
This patent strengthens Inventiva’s intellectual property with respect to lanifibranor in Japan for the indi... |
| 19.07.2024 | Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux | Daix (France), Long Island City (New York, United States), July 19, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecu... |
| 18.07.2024 | Inventiva annonce l'émission de certificats de royalties pour un montant de 20,1 millions d'euros | Certificats de royalties souscrits par Samsara BioCapital et des actionnaires existants BVF Partners, NEA, Sofinnova et Yiheng.
Royalties de 3 % sur les ventes nettes futures du lanifibranor aux Etats Unis, dans l’Union européenne et au Roy... |
| 18.07.2024 | Inventiva announces a €20.1 million issuance of royalty certificates | Royalty certificates subscribed by Samsara BioCapital and existing shareholders (BVF Partners, NEA, Sofinnova and Yiheng).
Royalty of 3% on future net sales of lanifibranor in the United States of America, the European Union and the United ... |
| 18.07.2024 | Inventiva announces a €20.1 million issuance of royalty certificates | Royalty certificates subscribed by Samsara BioCapital and existing shareholders (BVF Partners, NEA, Sofinnova and Yiheng).
Royalty of 3% on future net sales of lanifibranor in the United States of America, the European Union and the United ... |
| 05.07.2024 | Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position | Recruitment in NATiV3 clinical trial continues in both cohorts with over 80% of the targeted number of patients enrolled in the main cohort and 100% in the exploratory cohort of NATiV3.
Analysis of the baseline characteristics of all patien... |
| 05.07.2024 | Inventiva fait le point sur son programme clinique NATiV3 évaluant lanifibranor dans la MASH/NASH et sur sa situation financièr | Le recrutement dans l'essai clinique de phase III NATiV3 se poursuit dans les deux cohortes avec plus de 80% du nombre ciblé de patients recrutés dans la cohorte principale et 100% dans la cohorte exploratoire de NATiV3.
L'analyse des carac... |
| 05.07.2024 | Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position | Recruitment in NATiV3 clinical trial continues in both cohorts with over 80% of the targeted number of patients enrolled in the main cohort and 100% in the exploratory cohort of NATiV3.
Analysis of the baseline characteristics of all patien... |
| 21.06.2024 | Résultats des votes de l’Assemblée Générale Mixte des actionnaires réunies le 20 juin 2024 | Daix (France), Long Island City (New York, Etats-Unis), le 21 juin 2024 – Inventiva (Euronext Paris et Nasdaq : IVA) (la « Société »), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées pa... |
| 21.06.2024 | DESCRIPTIF DU PROGRAMME DE RACHAT D’ACTIONS AUTORISE PAR L'ASSEMBLEE GENERALE ORDINAIRE DU 20 JUIN 2024 | Daix, le 21 juin 2024 En application de l'article 241-2 du Règlement Général de l’Autorité des marchés financiers (AMF), le présent descriptif a pour finalité de présenter les objectifs ainsi que les modalités du programme de rachat d’actio... |
| 21.06.2024 | Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024 | Daix (France), Long Island City (New York, United States), on June 21, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies... |
| 21.06.2024 | Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024 | Daix (France), Long Island City (New York, United States), on June 21, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies... |
| 21.06.2024 | Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024 | Daix, 21 June 2024
Pursuant to Article 241-2 of the AMF General Regulations (Règlement Général de l’Autorité des marchés financiers), the purpose of this description is to present the objectives and terms of the Company’s share repurchase p... |
| 21.06.2024 | Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024 | Daix, 21 June 2024 Pursuant to Article 241-2 of the AMF General Regulations (Règlement Général de l’Autorité des marchés financiers), the purpose of this description is to present the objectives and terms of the Company’s share repurchase p... |
| 16.05.2024 | Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH | The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.
The recommendation was based on the unblinded review by the DMC of safety... |
| 16.05.2024 | Inventiva annonce la recommandation positive du quatrième DMC de l’étude clinique NATiV3 Phase III avec lanifibranor dans la MASH/NASH | Le Data Monitoring Committee recommande sur la base d’une revue planifiée des données de sécurité que l’étude clinique de Phase III continue sans modification du protocole actuel.
L’évaluation réalisée par le DMC est basée sur l’examen non ... |
| 03.04.2024 | Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F | Daix (France), Long Island City (New York, United States), April 3, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies fo... |
| 03.04.2024 | Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2023 et de son Rapport Annuel 2023 (« Form 20-F ») | Daix (France), Long Island City (New York, United States), le 3 avril 2024 – Inventiva (Euronext Paris et Nasdaq : IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement clinique de petites molécules admi... |
| 22.03.2024 | Inventiva annonce la date de publication et de présentation de ses résultats financiers 2023 | Daix (France), Long Island City (New York, Etats-Unis), le 22 mars 2024 – Inventiva (Euronext Paris et Nasdaq : IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement clinique de petites molécules adminis... |
| 22.03.2024 | Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results | Daix (France), Long Island City (New York, United States), March 22, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment... |
| 18.03.2024 | Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D | LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo.
Statistical significance was also achieved on several marke... |
| 18.03.2024 | Inventiva annonce les résultats positifs de l’essai clinique de Phase II, preuve de concept, LEGEND, combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de diabète de t... | LEGEND a atteint son critère principal d’efficacité en réduisant de manière significative le taux d’hémoglobine HbA1c dans les groupes recevant lanifibranor seul ou en combinaison avec empagliflozine, par rapport au groupe placebo.
Un effet... |
| 13.03.2024 | Inventiva annonce la présentation des résultats de son étude clinique de Phase IIa LEGEND combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de DT2 | Daix (France), Long Island City (New York, États-Unis), le 13 mars 2024 – Inventiva (Euronext Paris et Nasdaq : IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement clinique de petites molécules adminis... |
| 13.03.2024 | Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D | Daix (France), Long Island City (New York, United States), March 13, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies f... |
| 13.03.2024 | Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D | - |
| 07.03.2024 | Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed | - |
| 15.02.2024 | Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3 | Revenues of €17.5 million for the full year of 2023, compared to €12.2 million for 2022
Cash and cash equivalents at €26.9 million, short-term deposits at € 0.01 million2, and long-term deposit at €9.0 million3 as of December 31, 2023, comp... |
| 10.01.2024 | Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank | Inventiva intends to use the proceeds to fund part of its ongoing pivotal NATiV3 Phase III clinical trial evaluating lanifibranor in patients with NASH.
This second tranche carries an interest rate of 7% annually and has a maturity of 3 yea... |
| 21.11.2023 | Inventiva reports 2023 Third Quarter Financial Information¹ | Cash and cash equivalents at €43.8 million, short-term deposits at €0.03 million2, and long-term deposit at €5.0 million3 as of September 30, 2023, compared to €86.7 million, €1.0 million and €0.7 million as of December 31, 2022, respective... |
| 21.11.2023 | Inventiva publie ses informations financières du 3ème trimestre 2023¹ | Trésorerie et équivalents de trésorerie à 43,8 millions d’euros, dépôt à court terme à 0,03 million d’euros2 et dépôt à long terme à 5,0 millions d'euros3 au 30 septembre 2023, contre 86,7 millions d’euros, 1,0 million d’euros et 0,7 millio... |
| 24.06.2023 | Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association | /EIN News/ -- Daix (France), Long Island City (New York, United States), June 24, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for ... |
| 24.06.2023 | Inventiva annonce la présentation d’un abstract scientifique lors de la 82nd Scientific Sessions of the American Diabetes Association | /EIN News/ -- Daix (France), Long Island City (New York, United States), le 24 juin 2023 – Inventiva (Euronext Paris et Nasdaq : IVA) (la « Société »), société biopharmaceutique spécialisée dans le développement de petites molécules adminis... |
| 07.06.2023 | Inventiva annonce cinq présentations scientifiques lors de l’EASL International Liver Congress™ 2023 | Cinq présentations par poster démontrant :
La corrélation entre l'amélioration de la stéatose hépatique et une forte augmentation du taux d'adiponectine, l’amélioration du profil lipidique et du contrôle glycémique, observés chez les patien... |
| 25.05.2023 | Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 25 May 2023 | /EIN News/ -- Daix, 25 May 2023
Pursuant to Article 241-2 of the AMF General Regulations (Règlement Général de l’Autorité des marchés financiers), the purpose of this description is to present the objectives and terms of the Company’s share... |
| 25.05.2023 | DESCRIPTIF DU PROGRAMME DE RACHAT D’ACTIONS AUTORISE PAR L'ASSEMBLEE GENERALE ORDINAIRE DU 25 MAI 2023 | /EIN News/ -- Daix, le 25 mai 2023
En application de l'article 241-2 du Règlement Général de l’Autorité des marchés financiers (AMF), le présent descriptif a pour finalité de présenter les objectifs ainsi que les modalités du programme de r... |
| 04.01.2023 | Inventiva annonce des changements au développement clinique de lanifibranor notamment la préparation d’une nouvelle étude de Phase III chez les patients atteints de NASH avec une cirrhose compensée... | Les changements proposés devraient être bénéfiques pour le programme clinique de lanifibranor en réduisant le nombre de biopsies et la durée de l'étude, en offrant à terme à tous les patients dans l’étude un accès au traitement et en élargi... |
| 04.01.2023 | Inventiva announces changes to the clinical development of lanifibranor, including plans for a new Phase III trial in patients with NASH and compensated cirrhosis | Proposed changes are expected to be beneficial to the lanifibranor clinical program by reducing the number of biopsies and the trial duration, eventually offering all patients in the trial access to treatment and potentially expanding the a... |
| 12.12.2022 | Inventiva draws down €25 million tranche under Finance Contract with the European Investment Bank | Inventiva intends to use the proceeds to fund part of the pivotal Phase III clinical trial evaluating lanifibranor in patients with NASH
The €25 million supports Inventiva’s anticipated cash runway1 through the fourth quarter of 2023
/EIN N... |
| 12.12.2022 | Inventiva draws down €25 million tranche under Finance Contract with the European Investment Bank | - |
| 12.12.2022 | Inventiva annonce le tirage de la première tranche de 25 millions d'euros dans le cadre de son Contrat de Financement avec la Banque Européenne d'Investissement | Inventiva utilisera le produit de ce tirage pour financer une partie de l'étude clinique pivot de Phase III évaluant lanifibranor chez des patients atteints de la NASH
Ces 25 millions d'euros soutiendront la consommation de trésorerie1 d'In... |
| 31.10.2022 | Inventiva provides an update on the development of cedirogant by AbbVie | Daix (France), Long Island City (New York, United States), October 31, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatme... |
| 21.10.2022 | Inventiva announces a scientific presentation at the AASLD The Liver Meeting® 2022 | Daix (France), Long Island City (New York, United States), October 21, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatme... |
| 21.10.2022 | Inventiva announces a scientific presentation at the AASLD The Liver Meeting® 2022 | /EIN News/ -- Daix (France), Long Island City (New York, United States), October 21, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies f... |
| 21.10.2022 | Inventiva annonce la présentation d’un abstract scientifique lors du The Liver Meeting™ 2022 organisé par l’AASLD | /EIN News/ -- Daix (France), Long Island City (New York, Etats-Unis), le 21 octobre 2021 Daix (France) – Inventiva (Euronext Paris et Nasdaq : IVA), société biopharmaceutique spécialisée dans le développement clinique de petites molécules a... |
| 22.09.2022 | Inventiva reports its 2022 first-half financial results and provides a corporate update | Cash position1 at €87.2 million as of June 30, 2022, compared to €95.4 million as of December 31, 2021
Receipt of a €4 million milestone payment from Inventiva’s partner AbbVie for cedirogant Phase IIb clinical trial initiation accounted fo... |
| 21.09.2022 | Inventiva and Sino Biopharm announce licensing and collaboration agreement to develop and commercialize lanifibranor in Greater China | Sino Biopharm a leading Chinese pharmaceutical group, through CTTQ will oversee the development and commercialization of lanifibranor in Greater China
Lanifibranor is an orally-available small molecule with breakthrough therapy designation ... |
| 21.09.2022 | Inventiva and Sino Biopharm announce licensing and collaboration agreement to develop and commercialize lanifibranor in Greater China | Sino Biopharm a leading Chinese pharmaceutical group, through CTTQ will oversee the development and commercialization of lanifibranor in Greater China
Lanifibranor is an orally-available small molecule with breakthrough therapy designation ... |
| 07.09.2022 | Inventiva announces the schedule of publication and presentation of its 2022 Half-Year Financial Results | Daix (France), Long Island City (New York, United States), September 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapie... |
| 28.07.2022 | Inventiva Reports 2022 First-Half Financial Information¹ | Cash position2 at €87.2 m as of June 30, 2022
Revenues of €0.1 m in H1 2022
Inventiva entered into a finance loan and a warrant agreement for up to €50 million with the European Investment Bank (EIB)
Inventiva raised approximately €14.6m th... |
| 21.07.2022 | Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux | Daix (France), Long Island City (New York, United States), July 21, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment ... |
| 07.07.2022 | Inventiva announces the screening of the first patient in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with NASH and T2D | The Phase IIa Proof-of-Concept study is designed to assess the safety and efficacy of lanifibranor in combination with the SGLT2 inhibitor empagliflozin for the treatment of patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) a... |
| 04.07.2022 | Update on Inventiva's cash position and on the finance documentation with the European Investment Bank | Inventiva successfully raised approximately €14.6 million through a combination of its ATM Program for €9.3 million and new State-backed bank financing for €5.3 million
In accordance with the terms of the credit facility announced on May 16... |
| 16.06.2022 | Inventiva to host a webcast with Key Opinion Leaders following the EASL International Liver Congress™ 2022 | Update on Inventiva’s NATiV3 Phase III clinical trial evaluating lanifibranor in patients with NASH and fibrosis (stage F2/F3) non-cirrhotic by Prof. Sven Francque
Update on the current NASH landscape by Dr. Stephen Harrison
Presentation by... |
| 09.06.2022 | Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2022 | Three poster presentations showing
the beneficial effects of lanifibranor on markers of cardiometabolic health in patients with non-cirrhotic NASH fibrosis independent of weight gain observed.
the reduction of the FastTM score in associatio... |
| 03.06.2022 | Inventiva announces the presentation of a scientific abstract at the 82nd Scientific Sessions of the American Diabetes Association | Daix (France), Long Island City (New York, United States), June 3, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment o... |
| 23.05.2022 | Inventiva announces participation at several investors conferences in May and June 2022 | Daix (France), Long Island City (New York, United States), May 23, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for... |
| 20.05.2022 | Results of the votes of the Combined Shareholders’ Meeting of May 19, 2022 | Daix (France), Long Island City (New York, United States), May 20, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment o... |
| 16.05.2022 | Inventiva reports 2022 First Quarter Financial Information and provides clinical development update | Cash position2 at €80.5m as of March 31, 2022
The Group did not generate any revenue in Q1 2022
Signature of a €50 million bullet credit facility agreement with the European Investment Bank
Update on lanifibranor recruitment timing for Phas... |
| 16.05.2022 | Inventiva secures a €50 million credit facility from the European Investment Bank | This credit facility is intended to support the progress and expansion of Inventiva’s pipeline
The credit facility consists of two tranches of €25 million each
Credit agreement is part of the European Investment Bank’s strategy to support b... |
| 28.04.2022 | Combined General Meeting of May 19, 2022 - Availability of the preparatory documents | Daix (France), Long Island City (New York, United States), April 28, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment... |
| 28.04.2022 | Statement of total voting rights and shares forming the company’s share capital as of April 11, 2022 | Article R. 22-10-23 of the French Commercial Code
Market : Euronext Paris
ISIN code / Mnemo : FR0013233012 / IVA
Web site : www.inventivapharma.com
Date Number of Shares Outstanding Total voting rights,
gross (1) Total voting rights,
net (2... |
| 07.04.2022 | Inventiva announces the presentation of a scientific abstract at the next International Conference on Fatty Liver | Daix (France), Long Island City (New York, United States), April 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment ... |
| 11.03.2022 | Inventiva announces filing of its 2021 Universal Registration Document and 2021 Annual Report on Form 20-F | Daix (France), Long Island City (New York, United States), March 11, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment... |
| 08.03.2022 | Inventiva announces that its IND application for the Phase II combination trial with lanifibranor and empagliflozin in patients with NASH and T2D has been accepted by the FDA | FDA assessment concludes that the Phase II combination trial, LEGEND, may proceed
The initiation of the trial is planned for H1 2022 and the publication of topline results is expected for H2 2023
Daix (France), Long Island City (New York, U... |
| 07.03.2022 | Inventiva publie ses résultats annuels 2021 : Avancées majeures avec lanifibranor dans la NASH et cedirogant dans le psoriasis | Lancement de l’étude clinique de Phase III NATiV3 avec lanifibranor dans la NASH
Réception d’un paiement d’étape de 4 millions d’euros de la part d’AbbVie suite à l’inclusion du premier patient dans l’étude clinique de Phase IIb avec ce... |
| 07.03.2022 | Inventiva reports its 2021 Full-Year Results: key milestones achieved with lanifibranor in NASH and cedirogant in psoriasis | Initiation of the NATiV3 Phase III clinical trial with lanifibranor in NASH
Receipt of a €4 m milestone payment from AbbVie following the inclusion of the first patient in the ongoing Phase IIb clinical trial with cedirogant1 in patients wi... |
| 01.03.2022 | Inventiva announces participation at several conferences in March 2022 | Daix (France), Long Island City (New York, United States), March 1, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment ... |
| 28.02.2022 | Inventiva announces the schedule of publication and presentation of its 2021 Full-Year Financial Results | Daix (France), Long Island City (New York, United States), February 28, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatm... |
| 14.02.2022 | Inventiva reports cash position and revenues for Full-Year 2021 | Cash position2 at €95.4m as of December 31, 2021, compared to €105.7m on September 30, 2021, and €113.0m on December 31, 2020
Revenues of €4.2m in 2021 compared to €0.4m in 2020
Daix (France), Long Island City (New York, United States), Feb... |
| 01.02.2022 | Inventiva receives a EUR4 million milestone payment from AbbVie for cedirogant Phase IIb initiation | Daix (France), Long Island City (New York, United States) - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholi... |
| 01.02.2022 | Inventiva receives a 4 million milestone payment from AbbVie for cedirogant Phase IIb initiation | Daix (France), Long Island City (New York, United States), January 31, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatme... |
| 31.01.2022 | Inventiva receives a €4 million milestone payment from AbbVie for cedirogant Phase IIb initiation | Daix (France), Long Island City (New York, United States), January 31, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatme... |
| 20.01.2022 | Inventiva announces participation at several conferences in January and February 2022 | Daix (France), Long Island City (New York, United States), January 20, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatme... |
| 14.01.2022 | Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux | Daix (France), Long Island City (New York), January 14, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, muc... |
